EP2043679A4 - Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer - Google Patents

Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer

Info

Publication number
EP2043679A4
EP2043679A4 EP07799012A EP07799012A EP2043679A4 EP 2043679 A4 EP2043679 A4 EP 2043679A4 EP 07799012 A EP07799012 A EP 07799012A EP 07799012 A EP07799012 A EP 07799012A EP 2043679 A4 EP2043679 A4 EP 2043679A4
Authority
EP
European Patent Office
Prior art keywords
lymphocyte
cytotoxic
diagnosis
cancer
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07799012A
Other languages
German (de)
English (en)
Other versions
EP2043679A2 (fr
Inventor
Venky Ramakrishna
Mark M Ross
Ramila Philip
Lorrane Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunotope Inc
Original Assignee
Immunotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotope Inc filed Critical Immunotope Inc
Publication of EP2043679A2 publication Critical patent/EP2043679A2/fr
Publication of EP2043679A4 publication Critical patent/EP2043679A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
EP07799012A 2006-06-23 2007-06-25 Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer Withdrawn EP2043679A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/426,161 US7919467B2 (en) 2000-12-04 2006-06-23 Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PCT/US2007/072059 WO2007150077A2 (fr) 2006-06-23 2007-06-25 Immunogènes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prévention, du traitement et du diagnostic du cancer

Publications (2)

Publication Number Publication Date
EP2043679A2 EP2043679A2 (fr) 2009-04-08
EP2043679A4 true EP2043679A4 (fr) 2010-04-14

Family

ID=38834449

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07799012A Withdrawn EP2043679A4 (fr) 2006-06-23 2007-06-25 Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer

Country Status (5)

Country Link
US (2) US7919467B2 (fr)
EP (1) EP2043679A4 (fr)
AU (1) AU2007260824A1 (fr)
CA (1) CA2659124A1 (fr)
WO (1) WO2007150077A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2007519910A (ja) * 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
EP2476699B1 (fr) * 2006-10-17 2015-06-17 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides DEPDC1
TWI438207B (zh) * 2007-02-21 2014-05-21 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009032256A2 (fr) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Activateurs d'apc en combinaison avec une cellule sécrétant des cytokines et procédés pour les utiliser
CN102112492B (zh) * 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
JP5445969B2 (ja) * 2008-03-14 2014-03-19 学校法人北里研究所 膀胱癌の診断
ES2342506T3 (es) 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
WO2010010848A1 (fr) * 2008-07-22 2010-01-28 第一三共株式会社 Procédé de production d'anticorps dans une cellule de mammifère en culture en utilisant un chaperon moléculaire
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
CA2732980C (fr) 2008-08-05 2017-08-15 Toray Industries, Inc. Caprin-1 comme cible de diagnostic du cancer
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010039223A2 (fr) * 2008-09-30 2010-04-08 The Regents Of The University Of California Lymphocytes t immunogènes dérivés de protéines anti-virales et leurs procédés d’utilisation
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
AU2016204707B2 (en) * 2008-10-01 2018-02-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
EP2684568B1 (fr) * 2009-01-08 2017-11-15 International Institute of Cancer Immunology, Inc. Nouvel antigène de cancer EEF2
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
AU2011211700B2 (en) * 2010-02-04 2015-06-11 Toray Industries, Inc. Medicament for treating and/or preventing cancer
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2532364B1 (fr) 2010-02-04 2016-05-04 Toray Industries, Inc. Composition pharmaceutique comprenant des anticorps anti caprin-1 pour le traitement et/ou la prévention du cancer
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
US8937160B2 (en) 2010-02-04 2015-01-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
CN103429254A (zh) * 2010-10-11 2013-12-04 南加利福尼亚大学 分泌的热休克蛋白-90α（Hsp90α）片段作为用于对抗一系列人类实体肿瘤的单克隆抗体药物的疫苗或表位或小分子药物的靶点
EP2691420A4 (fr) 2011-03-28 2015-01-07 Harvard College Modulateurs de l'activité de la plexine b2
BR112014002613B1 (pt) 2011-08-04 2022-08-23 Toray Industries, Inc. Anticorpo ou um fragmento do mesmo, composição farmacêutica, dna, uso de um anticorpo e uso de uma composição farmacêutica
PL3351630T3 (pl) 2011-08-04 2020-05-18 Toray Industries, Inc. Kompozycja farmaceutyczna zawierająca przeciwciała przeciwko CAPRIN-1 do leczenia nowotworu i/lub zapobiegania nowotworowi
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
DK2740798T3 (en) 2011-08-04 2017-03-06 Toray Industries Drug composition for cancer treatment and / or prevention
DK2740793T3 (en) 2011-08-04 2018-01-22 Toray Industries PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2842887C (fr) 2011-08-12 2021-01-19 Oncotherapy Science, Inc. Peptides mphosph1 et vaccins les contenant
WO2013040015A2 (fr) * 2011-09-13 2013-03-21 Immunotope, Inc. Immunogènes induisant des lymphocytes t cytotoxiques utilisés pour la prévention, le traitement et le diagnostic du cancer
US9266958B2 (en) 2012-02-21 2016-02-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN104114581B (zh) 2012-02-21 2018-11-30 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN104114582B (zh) 2012-02-21 2018-12-21 东丽株式会社 癌的治疗和/或预防用药物组合物
CA2869123C (fr) 2012-03-30 2021-03-16 Toray Industries, Inc. Composition pharmaceutique renfermant des anticorps anti-caprins-1 destinee au traitement du cancer de la vesicule biliaire
CA2869120C (fr) 2012-03-30 2023-05-23 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prevention du cancer du foie
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP2876446B1 (fr) 2012-07-19 2018-12-26 Toray Industries, Inc. Procédé de détection de cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
CA2905418C (fr) * 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes de modulation de la cytotoxicite chimiotherapeutique
TWI777195B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三）
IL300761A (en) 2013-08-05 2023-04-01 Immatics Biotechnologies Gmbh Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2015038884A2 (fr) 2013-09-13 2015-03-19 Genentech, Inc. Compositions et méthodes de détection et de quantification d'une protéine cellulaire hôte dans des lignées cellulaires et polypeptides recombinés
CA2921999C (fr) 2013-09-13 2023-03-21 Genentech, Inc. Methodes et compositions comprenant un anticorps anti-il-13 et une phospholipase b-like 2 de hamster residuelle
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2015140567A1 (fr) * 2014-03-21 2015-09-24 Immunocore Limited Antigènes associés aux tumeur dérivés de la protéine traip
WO2015148960A1 (fr) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprenant des complexes hla soluble/ligand spécifique à m. tuberculosis et procédés de production et d'utilisation de ces dernières
US10000533B2 (en) 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
TWI711633B (zh) * 2014-09-24 2020-12-01 北海道公立大學法人札幌醫科大學 腫瘤抗原胜肽
MD3626731T2 (ro) * 2014-12-23 2022-01-31 Immatics Biotechnologies Gmbh Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și a altor cancere
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
AU2016218902A1 (en) 2015-02-09 2017-08-10 Rsem, Limited Partnership Novel minor histocompatibility antigens and uses thereof
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
CN112961213A (zh) 2015-08-12 2021-06-15 肿瘤疗法科学股份有限公司 Depdc1衍生的肽和包含它们的疫苗
WO2017053735A1 (fr) * 2015-09-23 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides dérivés de rpn2 humain utiles dans le traitement du cancer
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10793599B2 (en) 2015-10-08 2020-10-06 Oncotherapy Science, Inc. MPHOSPH1-derived peptide, and vaccine including same
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
US10383896B2 (en) 2015-12-11 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
CN106913863B (zh) * 2017-03-16 2020-10-27 北京热休生物技术有限公司 NUP188蛋白的多肽与热休克蛋白gp96的复合物在制备治疗与预防癌症药物中的应用
IT201800002694A1 (it) * 2018-02-15 2019-08-15 Sbarro Health Res Organization Inc MOLECOLE CHE INIBISCONO PKB/AKT COMPROMETTENDO LA FOSFORILAZIONE DI Ser941 DI RBL2/p130
US20210213058A1 (en) * 2018-03-12 2021-07-15 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN112345655A (zh) * 2019-08-06 2021-02-09 大理大学 一种胡蜂毒液指纹图谱的建立方法、胡蜂毒液指纹图谱及其应用
KR102372647B1 (ko) * 2019-08-16 2022-03-10 성균관대학교산학협력단 멜라닌 형성 검출용 조성물 및 피부 미백 물질의 스크리닝 방법
US20220334130A1 (en) * 2019-08-16 2022-10-20 Research & Business Foundation Sungkyunkwan University Melanogenesis detection method using fam86a
KR102265431B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
CN115060908A (zh) * 2021-07-01 2022-09-16 浙江大学 检测抗丝状肌动蛋白成帽蛋白β-IgG抗体的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046416A2 (fr) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Immunogenes induisant une reponse des lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic de cancers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5645994A (en) * 1990-07-05 1997-07-08 University Of Utah Research Foundation Method and compositions for identification of species in a sample using type II topoisomerase sequences
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
DE69219787T2 (de) 1991-11-29 1997-08-28 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
US6051397A (en) * 1993-11-16 2000-04-18 Max Planck Gesellschaft Zur Forderung Der Wissenschaften DNA encoding MCK-10, a novel receptor tyrosine kinase
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
US5763219A (en) * 1995-09-07 1998-06-09 Health Research, Incorporated Cyclin E variants and use thereof
US7270819B2 (en) * 1997-05-05 2007-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002078524A2 (fr) * 2001-03-28 2002-10-10 Zycos Inc. Determination de profils translationnels
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20090075304A1 (en) * 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090233318A1 (en) * 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046416A2 (fr) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Immunogenes induisant une reponse des lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic de cancers

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BONDURANT KRISTINA L ET AL: "Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAY 2005, vol. 11, no. 9, 1 May 2005 (2005-05-01), pages 3446 - 3454, XP009130221, ISSN: 1078-0432 *
FISK B ET AL: "Identification of an Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, vol. 181, no. 6, 1 June 1995 (1995-06-01), pages 2109 - 2117, XP009030958, ISSN: 0022-1007 *
FISK BRYAN ET AL: "Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes", CANCER RESEARCH, vol. 57, no. 1, 1997, pages 87 - 93, XP009130225, ISSN: 0008-5472 *
HUYNH KHANH D ET AL: "BCoR, a novel corepressor involved in BCL-6 repression", GENES AND DEVELOPMENT, vol. 14, no. 14, 15 July 2000 (2000-07-15), pages 1810 - 1823, XP009130222, ISSN: 0890-9369 *
RAMAKRISHNA V ET AL: "GENERATION AND PHENOTYPIC CHARACTERIZATION OF NEW HUMAN OVARIAN CANCER CELL LINES WITH THE IDENTIFICATION OF ANTIGENS POTENTIALLY RECOGNIZABLE BY HLA-RESTRICTED CYTOTOXIC T CELLS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 73, no. 1, 26 September 1997 (1997-09-26), pages 143 - 150, XP000892416, ISSN: 0020-7136 *
RAMAKRISHNA VENKATESH ET AL: "Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 6, 1 June 2003 (2003-06-01), pages 751 - 763, XP009103655, ISSN: 0953-8178 *
ROSENBERG S A ET AL: "A NEW ERA FOR CANCER IMMUNOTHERAPY BASED ON THE GENES THAT ENCODE CANCER ANTIGENS", IMMUNITY, CELL PRESS, US, vol. 10, no. 3, 1 March 1999 (1999-03-01), pages 281 - 287, XP000918298, ISSN: 1074-7613 *
YOKOKAWA JUNKO ET AL: "Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 SEP 2005, vol. 11, no. 17, 1 September 2005 (2005-09-01), pages 6342 - 6351, XP009130224, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2007150077A8 (fr) 2008-08-28
WO2007150077A2 (fr) 2007-12-27
CA2659124A1 (fr) 2007-12-27
AU2007260824A1 (en) 2007-12-27
US7919467B2 (en) 2011-04-05
EP2043679A2 (fr) 2009-04-08
US20080207497A1 (en) 2008-08-28
US20110142919A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
EP2043679A4 (fr) Immunogenes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prevention, du traitement et du diagnostic du cancer
EP2061503A4 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques pour la prévention, le traitement et le diagnostic du cancer
EP2470200A4 (fr) Immunogènes cytotoxiques induisant des lymphocytes t pour prévenir, traiter et diagnostiquer un cancer
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HK1224200A1 (zh) 用於治療胰腺癌的藥物
IL197315A0 (en) Treatment of cancer
EP2257647A4 (fr) Procédés et compositions fondés sur micro arn pour le diagnostic, le pronostic et le traitement du cancer de l'estomac
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
IL202014A0 (en) A synergistic pharmaceutical combination for the treatment of cancer
EP2165715A4 (fr) Agent thérapeutique contre le cancer et procédé de traitement du cancer
EP2049139A4 (fr) Traitement de tumeurs exprimant ras
EP2029156A4 (fr) Polythérapie pour traiter le cancer
EP1979487A4 (fr) Compositions de cobalamine pour le traitement du cancer
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2198041A4 (fr) Méthode et composition de diagnostic et traitement du cancer
EP1986656A4 (fr) Composes de withacnistine pour le traitement du cancer
WO2008051421A3 (fr) Composés cytotoxiques de peptides
IL226362A0 (en) compounds, and methods for treating cancer
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0600903D0 (en) Treatment of cancer
GB0710871D0 (en) Cancer treatment
GB0604114D0 (en) Combinations for the treatment of cancer
GB0622581D0 (en) Treatment of cancer
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100612